# Actithera

> Actithera is a radiopharmaceutical biotech developing next-generation radioligand therapies (RLTs) for cancer. Founded in 2021 by medicinal chemist Andreas Goutopoulos and based in Cambridge, Massachusetts and Oslo, Norway, the company uses a proprietary, chemistry-led platform to design covalent small-molecule radioligands that lodge inside tumors, deliver targeted radiation, and clear quickly from healthy tissue. Its isotope-agnostic approach is engineered to match the residence time of a drug in a tumor to the half-life of long-lived radionuclides, with a lead program targeting Fibroblast Activation Protein (FAP). Actithera raised an oversubscribed $75.5M Series A in July 2025.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States (and Oslo, Norway)
- **Founders:** Andreas Goutopoulos (CEO and Founder)
- **Team size:** ~33 employees
- **Products:** Radioligand Therapy (RLT) Discovery Platform, Lead FAP Program
- **Notable:** Closed an oversubscribed $75.5M Series A in July 2025., Assembled a syndicate of leading life-science investors across the US and Europe., Advanced a lead FAP radioligand asset into IND-enabling / clinical-preparation studies.

## Products & services

- **Radioligand Therapy (RLT) Discovery Platform** — A proprietary, chemistry-led platform combining rational drug design and radiochemistry to create covalent small-molecule radioligands and modified peptides. Built on three pillars: covalent-targeting strategies to optimize tumor residence time, approaches to enhance tumor retention and selectivity, and an isotope-agnostic philosophy compatible with alpha and beta emitters.
- **Lead FAP Program** — A development candidate targeting Fibroblast Activation Protein (FAP), a protein expressed across many solid tumors, being prepared for clinical trials in multiple cancer indications with best-in-class ambitions on pharmacokinetics and tumor specificity.

## Achievements

- Closed an oversubscribed $75.5M Series A in July 2025.
- Assembled a syndicate of leading life-science investors across the US and Europe.
- Advanced a lead FAP radioligand asset into IND-enabling / clinical-preparation studies.
- Built a differentiated, covalent, isotope-agnostic radioligand discovery platform.

## Latest updates

- **2025-07** — Raised an oversubscribed $75.5M Series A co-led by M Ventures, Hadean Ventures, Sofinnova Partners and 4BIO Capital to advance its lead FAP asset and platform.
- **2025-07** — Expanded its board with representatives from Hadean, Sofinnova, 4BIO and Bioqube Ventures.
- **2025** — Appointed Dr. Darshan Dalal as Chief Medical Officer to lead clinical development.

## Links

- Website: https://actithera.com
- LinkedIn: https://www.linkedin.com/company/actithera

---

Profile page: https://yespress.io/actithera
Published by YesPress — https://yespress.io
Last updated: 2026-07-22